Hepoxilin analogs, potential new therapeutics in disease

Current Pharmaceutical Design

Volumn 12, Issue 8, 2006, Pages 963-969

  Pace Asciak, C R ^a,b   Li, X ^a   Qiao, N ^a   Reynaud, D ^a   Demin, P ^a   Abdelhaleem, M ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; Cancer; Hepoxilin analogs; Inflammation; PBTs; Proof of concept; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BCR ABL PROTEIN; BLEOMYCIN; HEPOXILIN A; HEPOXILIN B; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN TYROSINE KINASE; THROMBOXANE A2; THROMBOXANE RECEPTOR;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKEMIA CELL; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 33646012988     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776055903     Document Type: Review

References (57)

1. Pace-Asciak CR, Granström E, Samuelsson B. Arachidonic acid epoxides: Isolation and structure of 2 hydroxy epoxide intermediates in the formation of 8, 11, 12-trihydroxy eicosatrienoic acid and 10, 11, 12-trihydroxy eicosatrienoic acid. J Biol Chem 1983; 258: 6835-6840.
2. Pace-Asciak CR, Martin JM. Hepoxilin, a new family of insulin secretagogues formed by intact rat pancreatic islets. Prostagl Leukotriene and Med 1984; 16: 173-180.
3. 3 induces changes in cytosolic calcium, intracellular pH and membrane potential in human neutrophils. Biochem J 1990; 266: 63-68.
4. 3 inhibits the rise in free intracellular calcium evoked by formyl-methionyl-leucyl-phenylalanine, platelet-activating factor and leukotriene BBiochem J 1993; 295: 393-397.
5. 3-specific binding with calcium-mobilizing actions in human neutrophils. In: Schrör K, Pace-Asciak CR Eds, Mediators in the Cardiovascular System - Regional Ischemia, Agents and Actions Supplements, Basel, Birkhauser Verlag 1995; Vol 45, pp 291-296
6. 3-specific binding in human neutrophils. Biochem J 1996; 313: 537-541.
7. 3 as a lipid substrate. Biochim Biophys Acta 1986; 875: 406-409.
8. 3-C, a glutathione conjugate. Biochim Biophys Acta Lipids Lipid Metab 1991; 1084: 60-68.
9. 4 omega-hydroxylase. Biochim Biophys Acta Lipids Lipid Metab 1997; 1348: 287-298.
10. 3 and BTetrahedron Lett 1993; 34: 4305-4308.
11. Cooper J. Pulmonary fibrosis. Pathways are slowly coming to light. Am J Respir Cell Mol Biol 2000; 22: 520-523.
12. Adamson I. Drug-induced pulmonary fibrosis. Environ Health Perspect 1984; 55: 25-36.
13. Nici L, Santos-Moore A, Kuhn C, Calabresi P. Modulation of bleomycin-induced pulmonary toxicity in the hamster by the antioxidant amifostine. Cancer 1998; 83: 2008-2014.
14. Kelley J, Newman R, Evans J. Bleomycin-induced pulmonary fibrosis in the rat. J Lab Clin Med 1980; 96: 954-964.
15. Cooper J, Zitnik R, Matthay R. Mechanisms of drug-induced pulmonary disease. Ann Rev Med 1988; 39: 395-404.
16. Gurujeyalakshmi G, Giri S. Molecular mechanisms of anti-fibrotic effect of interferon-gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 1995; 21: 791-808.
17. Giri SN, Hollinger MA. Effect of nordihydroguaiaretic acid and ibuprofen on bleomycin and hyperoxia-induced changes in lung superoxide dismutase, prostaglandins and lethality. Arch Toxicol 1996; 70: 271-276.
18. Wang MM, Reynaud D, Pace-Asciak CR. In vivo stimulation of 12(S)-lipoxygenase in the rat skin by bradykinin I and platelet activating factor: formation of 12(S)-HETE and hepoxilins, and actions on vascular permeability. Biochim Biophys Acta Lipids Lipid Metab 1999; 1436: 354-362.
19. 3) on bradykinin and PAF-evoked potentiation of vascular leakage in rat skin. Gen Pharmacol 1999; 33: 377-382.
20. 3 in human epidermis. J Invest Dermatol 2000; 114: 554-559.
21. Jankov RP, Luo X, Demin P, Aslam R, Hannam V, Tanswell AK, Pace-Asciak CR. Hepoxilin analogs inhibit bleomycin-induced pulmonary fibrosis in the mouse. J Pharm Exp Ther 2002; 301: 435-440.
22. Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 1974; 71: 3400-3404.
23. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998.
24. Hammarstrom S, Lindgren JA, Marcelo C, Duell EA, Anderson TF, Voorhees JJ. Arachidonic-acid transformations in normal and psoriatic skin. J Invest Dermatol 1979; 73: 180-183.
25. Hammarstrom S, Diczfalusy U. Biosynthesis of thromboxanes. Samuelsson B, Ramwell PW, Paoletti R. (eds.). Advances in Prostaglandin and Thromboxane Research 1980; 6: 267-274.
26. Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol 1993; 72: 278-284.
27. Parellada PP, Planas JM. Action of selective inhibitor of thromboxane synthetase on experimental thrombosis induced by arachidonic acid in rabbits. Lancet 1977; 40.
28. Randall MJ, Wilding RIR. Acute arterial thrombosis in rabbits: reduced platelet accumulation after treatment with thromboxane synthetase inhibitor dazoxiben hydrochloride, (UK-37, 248-01). Thromb Res 1982; 28: 607-616.
29. Fiedler VB, Perzborn E, Seuter F, Rosentreter U, Böshagen H. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1, 2, 3, 4-tetrahydro-9-carbazoleprop anoic acid. Arzneimittelforschung 1989; 39: 1527-1530.
30. Silver RM, Edwin SS, Trautman MS, Simmons DL, Branch DW, Dudley DJ, Mitchell MD. Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. J Clin Invest 1995; 95: 725-731.
31. Wolkow PP, Bartus JB, Gryglewski RJ. Pneumotoxicity of lipopolysaccharide in nitric oxide-deficient rats is limited by a thromboxane synthase inhibitor. J Physiol Pharmacol 1997; 48: 645-653.
32. 2 synthase-2 by lipopolysaccharide in human polymorphonuclear leukocytes. Eur J Haematol 1999; 63: 94-102.
33. Vane JR. The mode of action of aspirin-like drugs. Agents & Actions 1978; 8: 430.
34. Willis AL. Platelet aggregation mechanisms and their implications in haemostasis and inflammatory disease. In: Inflammation, handbook of experimental pharmacology. Eds, Ferreira SH, Vane JR, Berlin, Springer-Verlag, 1978; pp 138-205.
35. 2 balance: pathophysiological and therapeutic implications. Br Med Bull 1983; 39: 271-276.
36. Harada Y, Kawamura M, Hatanaka K, Saito M, Ogino M, Obno T, Ogino K, Yang QS. Differing profiles of prostaglandin formation inhibition between selective prostaglandin H synthase-2 inhibitors and conventional NSAIDs in inflammatory and non-inflammatory sites of the rat. Prostaglandins 1998; 55: 345-358.
37. Reynaud D, Sun A, Demin PM, Pace-Asciak CR. Novel platelet antiaggregating substances. Biochem Biophys Res Commun 2001; 284: 580-582.
38. Pace-Asciak CR, Reynaud D, Demin P, Aslam R, Sun A. A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. J Pharmacol Exper Ther 2002; 301: 618-624.
39. Qiao N, Reynaud D, Demin P, Halushka PV, Pace-Asciak CR. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPα isoform in transfected COS-7 cells. J Pharmacol Exper Therap 2003; 307: 1142-1147.
40. Reynaud D, Clark D, Qiao N, Rand ML, Pace-Asciak CR. The bepoxilin stable analogue, PBT-3, inhibits primary, platelet-related hemostasis in whole blood measured in vitro with the PFA-1Throm Res 2003; 112: 245-248.
41. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 19Mod Pathol 2000; 13: 193-207.
42. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-214.
43. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, Cory S, Adams JM. A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 1989; 9: 2798-2805.
44. Heisterkamp N, Jenster G, ten-Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukema in bcr/abl transgenic mice. Nature 1990; 344: 251-253.
45. Diomede L, Colotta F, Piovani B, Re F, EModest EJ, Salmon M. Induction of apoptosis in human leukemic cels by the ether lipid 1-octadecyl-2-methyl-ac-glycero-3-phosphocholine. A possible basis for its selective action. Int J Cancer 1993; 53: 124-130.
46. Lozzio CB, Lozzio BB. Human chorionic myelogenous leukemia cell line with positive philadelphia chromosome. Blood 1975; 45: 321.
47. Lozzio BB, Lozzio CB. Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int J Cancer 1977; 19: 136.
48. Martin SJ, Lennon SV, Bonham AM, Cotter TG. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis. J Immunol 1990; 145: 1859-1867.
49. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
50. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92: 1042-1053.
51. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
52. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1: 31-36.
53. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KNH. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96: 2246-2253.
54. Qiao N, Lam J, Reynaud D, Abdelhaleem M, Pace-Asciak CR. The hepoxilin analog PBT-3 induces apoptosis in BCR-ABL-positive K562 leukemia cells. Anticancer Res 2003; 23: 3617-3622.
55. Cetkovic-Cvrlje M, Tibbles HE. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. Cuff Pharm Design 2004; 10(15): 1767-84.
56. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Design 2004; 10(6): 647-57.
57. Stefanidakis M, Koivunen E. Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells. Curr Pharm Design 2004; 10(24): 3033-44.